We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.67%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$735M
AUM Growth
–
Cap. Flow
+$730M
Cap. Flow %
99.32%
Top 10 Hldgs %
55.66%
Holding
60
New
60
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$78.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$65.1M
3
CELG
Celgene Corp
CELG
+$61.4M
4
BIIB icon
Biogen
BIIB
+$41M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$35.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 84.4%
2 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$298M
$7.9M 1.07%
+68,115
New +$9.39M
AGN
27
DELISTED
Allergan Inc
AGN
$7.84M 1.07%
+93,077
New +$9.66M
ILMN icon
28
Illumina
ILMN
$31B
$7.77M 1.06%
+106,749
New +$6.83M
ALR
29
DELISTED
Alere Inc
ALR
$7.76M 1.05%
+316,553
New +$8.18M
IRWD icon
30
Ironwood Pharmaceuticals
IRWD
$614M
$7.64M 1.04%
+917,052
New +$11.1M
ARIA
31
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$7.22M 0.98%
+412,965
New +$7.32M
IPXL
32
DELISTED
Impax Laboratories, Inc.
IPXL
$6.88M 0.94%
+344,683
New +$6.12M
IMGN
33
DELISTED
Immunogen Inc
IMGN
$6.53M 0.89%
+393,773
New +$6.38M
MCK icon
34
McKesson
MCK
$101B
$6.51M 0.89%
+56,862
New +$6.33M
FRX
35
DELISTED
FOREST LABORATORIES INC
FRX
$6.01M 0.82%
+146,500
New +$5.66M
SGNT
36
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$5.67M 0.77%
+270,031
New +$4.83M
ALKS icon
37
Alkermes
ALKS
$8.39B
$5.59M 0.76%
+194,870
New +$5.68M
UNH icon
38
UnitedHealth
UNH
$383B
$5.4M 0.73%
+82,436
New +$5.13M
BAX icon
39
Baxter International
BAX
$13.8B
$5.38M 0.73%
+143,000
New +$5.48M
IDXX icon
40
Idexx Laboratories
IDXX
$44.1B
$5.05M 0.69%
+112,530
New +$4.92M
ENDP
41
DELISTED
Endo International plc
ENDP
$4.64M 0.63%
+126,215
New +$4.54M
ARAY icon
42
Accuray
ARAY
$33.9M
$4.2M 0.57%
+731,943
New +$3.7M
BMRN icon
43
BioMarin Pharmaceuticals
BMRN
$11.7B
$4.18M 0.57%
+75,000
New +$4.67M
CVS icon
44
CVS Health
CVS
$134B
$4.09M 0.56%
+71,591
New +$4.15M
ACOR
45
DELISTED
Acorda Therapeutics
ACOR
$3.72M 0.51%
+941
New +$3.87M
MACK
46
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$3.62M 0.49%
+68,329
New +$3M
ELN
47
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
$3.43M 0.47%
+242,500
New +$3M
IPCI
48
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$2.81M 0.38%
+173,500
New +$3.2M
RIGL icon
49
Rigel Pharmaceuticals
RIGL
$704M
$2.76M 0.38%
+82,710
New +$3.75M
AUXL
50
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$2.12M 0.29%
+127,520
New +$2.04M
1
2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Tekla Capital Management, which disclosed 60 positions worth $735M. Its ten largest holdings account for 56% of the portfolio.

Its largest position is Gilead Sciences: 1,504,712 shares worth $77.1M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, followed by Financials.

  • Tekla Capital Management's largest Q2 2013 buy was Gilead Sciences: 1,504,712 shares worth $77.1M.
  • Tekla Capital Management's ten largest holdings make up 56% of its $735M portfolio in Q2 2013.
  • Tekla Capital Management disclosed 60 positions in Q2 2013, its first 13F filing on record.

Based on Tekla Capital Management's 13F filing for Q2 2013, filed 31 Jul 2013.